Company Started its operation with just five psychiatry brands in the year 1983. Company has emerged as one of the leading pharmaceutical companies in India, and one of the largest Indian companies in the US generic market. In India Company is the largest specialty prescription company. In the US, it offers a comprehensive portfolio of generics including controlled substances and dermatologicals. Sun Pharma has presence in 40 other markets. In the US, Company has built a strong pipeline of generics, directly and through its subsidiaries Caraco and Sun Pharmaceutical Inc.

Sun Pharma is making a joint venture with Merck & Co to develop, manufacture and sell new combination and versions of branded generics in emerging markets. Under this joint venture, the parent company, Sun Pharma said that a research-oriented listed company, SPARC will contribute its technology for the Joint Venture (JV) wherever necessary. Sun Pharma has gathered 16% to Rs 91.

Dilip Shanghvi, chairman and managing director of the SPARC said that for contributing its services to the joint venture, the company will get upfront and milestone payments.

On Thursday, Sun Pharmaceutical Industries expressed that it has established endorsement through US health watchdog to market standard Tiazac capsules and Clarinex tablets, make use in take care of nasal allergic reaction and hypertension, correspondingly, in the American marketplace.

The Mumbai- pedestal group for its abbreviated new drug application (ANDA) has established endorsement through US Food and Drug Administration (USFDA) to promote a generic edition of Clarinex tablets of Schering Plough's, Sun Pharma expressed in a declaration.

Stock market analyst Anil Singhvi has maintained 'buy' rating on Sun Pharmaceutical Industries Limited stock with an intra-day target of Rs 2450.

According to analyst, the stock can be purchased with a stop loss of Rs 2300.

The stock of the company, on Nov 11, closed at Rs 2331.90 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 2349 and a low of Rs 1407 on BSE.

Current EPS & P/E ratio stood at 86.97 and 27.16 respectively.

The most valuable pharma company in the Indian market, Sun Pharma has recently announced that the company has recently bagged the control of the Israel based pharma company, Taro.

It is to be mentioned that the company has won a three year bitter battle by closing the deal. It may be noted here that Sun Pharma has been working for a very long time on its strategy to buy niche pharma companies.

According to the deal announced by the company, it now has close to 48.7% holding and 65.8% voting rights in Taro.

Stock market analyst Vijay Bhambwani has maintained 'buy' rating on Sun Pharmaceutical Industries Ltd stock with a target of Rs 1820-1825.

According to analyst, the investors can buy the stock with stop loss of Rs 1680.

Today, the stock opened at Rs 1755 on the Bombay Stock Exchange (BSE).

Current EPS & P/E ratio stood at 65.23 and 26.62 respectively.

The share price has seen a 52-week high of Rs 1846 and a low of Rs 1159 on BSE.

Stock market analyst Hemen Kapadia is of the view that investors can buy Sun Pharma Industries Ltd stock to achieve an intraday target of Rs 1720.

According to analyst, the investors can buy the stock at Rs 1700 with stop loss of Rs 1690.

The shares of the company, on June 16, closed at Rs 1700.15 the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 1846 and a low of Rs 1103 on BSE.

Current EPS & P/E ratio stood at 65.23 and 26.27 respectively.

Technical Analyst Rajesh Jain of SMC Global has maintained 'buy' rating on Sun Pharmaceutical Industries Limited stock to achieve a target of Rs 1680 in 2-4 weeks.

According to analyst, investors can buy the stock with a stop loss of Rs 1500.

Today (May 14), the shares of the company opened at Rs 1572.05 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 1846 and a low of Rs 1103 on BSE.

Current EPS & P/E ratio stood at 65.25 and 24.40 respectively.

United States Food and Drug Administration (FAD) had contracted India's Sun Pharmaceuticals Limited to market generic version of GlaxoSmithKline's Wellbutrin SR Extended Release tablets.

Company in a press release expressed that Wellbutrin is used for treating serious depressive disorders.

Company also told that Wellbutrin will be alike the generic Bupropion Hydrochoride Extended Release tablets. These are available in 3 strengths: 100mg, 150mg and 200mg.

All these tablets with different strengths jointly account for annual sale of approximately $ 300 million in the US.

Sun Pharmaceutical Industries has received tentative authorization from USFDA for ANDA for generic Gleevec imatinib meyslate tablets.

The official permission has been granted for the pills in the strength of 100 mg and 400 mg. Gleevec imatinib meyslate tablets are the therapeutical variants of Novartis's Gleevec tablets.

Sun Pharmaceutical Industries, India's largest drug firm in terms of market capitalization, has received USFDA approval for an abbreviated new drug application (ANDA) for ketorolac tromethamine ophthalmic solution, 0.5%.

The ophthalmic solution, which has annual sales of approximately $40 million in the US market, is generic version of Acular ophthalmic solution, 0.5%, of Allergan.

The solution is indicated for temporary relief of ocular itching due to seasonal allergic conjunctivitis. The drug is also used in the cure of post operative inflammation in patients who have gone through cataract extraction.

Sun Pharmaceutical Industries, leading India-based drug manufacturer, has announced that it has received sanction from U.S. Food and Drug Administration to introduce its generic version of GlaxoSmithKline's Imitrex tablets.

According to the company, Imitrex tablets are used for treating migraine and have decent sales numbers in the country.

Sun Pharmaceutical Industries Limited announced today it has, along with its subsidiaries, executed a settlement agreement with MedImmune, stipulating the dismissal of the lawsuits filed in the United States District Court for the District of Maryland regarding the submission of an Abbreviated New Drug Application (ANDA) for a generic version of Ethyol.

Sun Pharmaceutical, India’s fourth largest drug manufacturer, has reported substantial dip of 67.32% in its consolidated net profit in the first quarter ended June 30, 2009.

During the reporting period, the company has clocked consolidated net profit of Rs 164 crore.

In the similar period of previous fiscal, company’s net profit figure stood at Rs 501crore.

The company has attributed the fall in net profit to drop in domestic sales as well as its US subsidiary - Caraco Pharma.

Sun Pharmaceutical has informed that it has entered into agreements with Forest Laboratories Inc., Forest Laboratories Holdings Ltd., and H. Lundbeck A/S to settle legal proceedings related to Lexapro (escitalopram oxalate) tablets.

The deal has been formalized between Sun Pharma and its subsidiaries along with Caraco Pharmaceutical (also Sun's US-based subsidiary), and Forest Laboratories, Forest Laboratories Holdings and H. Lundbeck.

However, these agreements will be subject to review by the US Federal Trade Commission.

Sun Pharmaceutical Industries Limited announced that USFDA has granted its subsidiary an approval for an Abbreviated New Drug Application (ANDA) for generic Casodex bicalutamide tablets.

These bicalutamide tablets, USP 50 mg are therapeutically equivalent to Cadodex tablets from AstraZeneca.

Reports suggest that, Casodex tablets have annual sales of approximately USD 314 million in the US.

Sun Pharmaceutical Industries Ltd, a leading India based drug major has informed that it has received tentative approval from USFDA for company's

Abbreivated New Drug Application (ANDA) for generic Optivar, azelastine ophthalmic solution 0.05%.

The pharmaceutical firms stated in a communiqué that sterile azelastine hydrochloride ophthalmic solution is the therapeutically equivalent to Optivar Opthalmic Solution 0.05% of Medpointe Pharmaceuticals.

Sun Pharmaceutical Industries Ltd, a leading India based drug major has informed that the US Food and Drug Administration (USFDA) has given approval for its New Drug Application for generic Accupril, quinapril hydrochloride tablets.

These quinapril hydrochloride tablets, therapeutically equivalent to Accupril tablets from Pfizer, are available in four potencies including 5 mg, 10 mg, 20 mg and 40 mg.

The sources close to company said that these strengths of tablets have annual sales of approximately USD 45 million in the US.